Hybrid mass spectrometer with liquid chromatography system

质谱分析（MS）是生物医学和基础研究的核心技术。定义的标准、协议和软件使广泛的研究团体可以访问它。高通量质谱（HT-MS）在蛋白质组学和代谢组学中形成了一个新的分支，能够为流行病学研究和复杂的系统生物学实验生成高质量的数据集（100 - 1000个样本）。统计学、系统医学和计算机科学（机器和深度学习）的新方法使HT-MS具有巨大的潜力，例如，随着时间的推移详细绘制发育过程，了解微生物组，预测疾病的进程，对患者进行分层（例如进行个性化治疗）和调查复杂的疾病机制。高通量蛋白质组学平台的结构与传统工艺的关键要素不同。由于样品数量多，个体分析速度更快，成本更低。为了确保历年数据的可比性，可以精确地确定变异的技术来源，例如批次效应。这是通过专门的实验、技术和组织过程来实现的。在过去的18个月中，“Facility ht -质谱”能够为高分析物浓度样品（例如血浆/血清，培养细胞）建立基础设施。正在进行的分析已经涵盖了1万多个人类和其他真核生物蛋白质组，包括对covid - 19的研究、麻醉后影响认知的因素和复合筛选。目前，来自10万基因组计划的6000个样本，来自CHRIS研究（EURAC研究所阿尔卑斯山人口研究）的4000个受试者，以及用于2型糖尿病EPIC-Interact研究（MRC剑桥）的1400个样本正在进行中。因此，charit<s:1> Core Facility HT-MS迅速成为欧洲为数不多的具有高通量能力的蛋白质组学中心之一。我们申请的仪器是对资源有限的项目平台的补充。目前这种能力的缺乏排除了基础研究的中心项目（如facs分选细胞、原代培养、干细胞、FFPE切片、液体和微生物间谍）。

Mass spectrometry (MS) is a central technology in biomedical and basic research. Defined standards, protocols, and software make it accessible to a broad research community. High-throughput mass spectrometry (HT-MS) forms a new branch within proteomics and metabolomics and enables the generation of high-quality data sets (100s – 1000s of samples) for epidemiological studies as well as complex systems biology experiments. New methods of statistics, systems medicine and computer science (machine and deep learning) boost HT-MS with immense potential, e.g. to map developmental processes in detail over time, to understand microbiomes, to predict the course of diseases, to stratify patients (e.g. for personalized therapy) and to investigate complex disease mechanisms. The structure of a high-throughput proteomics platform differs in key elements from conventional processes. Due to the high number of samples, individual analyses med to be faster and cheaper. To assure comparability of data over the years, technical sources of variability, e.g., batch effects, can be precisely determined. This is achieved by specialized experimental, technical and organizational processes. In the last 18 months, the ‘Facility HT-Mass Spectrometry’ was able to establish the infrastructure for samples of high analyte concentration (e.g. plasma/serum, cells from culture). Ongoing analyses already cover more than 10,000 human and other eukaryotic proteomes, including studies on COVID19, the factors influencing cognition after anesthesia, and compound screens. Currently, 6,000 samples from the 100,000 Genomes Project, 4,000 subjects from the CHRIS study (Alpine population study by the EURAC Institute), and 1,400 samples for the EPIC-Interact study on type 2 diabetes (MRC Cambridge) are in progress. As a result, the Charité Core Facility HT-MS has quickly established itself as one of the few European proteomics centers with high-throughput capacity. The instrument we are applying for complements the platform for projects with limited source material. The current lack of such a capacity excludes central projects of basic research (e.g. FACS-sorted cells, primary cultures, stem cells, FFPE sections, liquid, and microbiospies).